Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia

TOKYO and STAMFORD, Conn., March 11, 2019 -- (Healthcare Sales & Marketing Network) -- Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharm... Biopharmaceuticals, FDA Eisai, Imbrium Therapeutics, Lemborexant, Insomnia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news